Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Intravenous Levetiracetam in Neonatal Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Newborns admitted to any of the study sites with electrographic seizures seizures.~2. Term infants gestational age \>36 weeks less than 2 weeks of age.~3. Greater than 2200 grams.~4. Infants for whom parental consent to participate in the study is obtained.~Exclusion Criteria:~1. Infants who are already receiving anticonvulsants~2. If serum creatinine is greater than 1.6mM~3. If seizures are due to correctable metabolic abnormalities (i.e. hypoglycaemia, hypocalcemia, hyponatremia)~4. Subjects in whom death seems imminent, as assessed by the neonatologist.

- Gender: ALL
- Minimum Age: 15 Minutes
- Maximum Age: 14 Days
- Healthy Volunteers: f

Study Arms:
- Intravenous levetiracetam (Type: EXPERIMENTAL): Intravenous levetiracetam 40 to 60 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
- Intravenous phenobarbital (Type: ACTIVE_COMPARATOR): Intravenous phenobarbital 20 to 40 mg/kg load. 1.5 mg/kg 8 hourly maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).